Maxwell Meng

Dr. Maxwell Meng is a distinguished academic urologic surgeon at the University of California, San Francisco (UCSF), affiliated with the Department of Urology in the School of Medicine. He specializes in urologic cancers, minimally invasive and robotic surgery, and is actively engaged in developing new treatment technologies.

Education:

• Bachelor of Arts (A), Biochemical Sciences, Harvard College, 1991
• Doctor of Medicine (MD), Johns Hopkins School of Medicine, 1995
• General Surgery & Urology Residency, UCSF, 1995–2001
• Laparoscopic Fellowship, UCSF, 2001–2002
• Oncology Fellowship, UCSF, 2002–2003

Dr. Meng’s research spans urologic oncology, with focus on renal cell carcinoma, bladder cancer, and prostate cancer. His work integrates clinical innovation, molecular profiling, immunology, and health services research, particularly examining health disparities and quality of life. He has led and contributed to pivotal clinical trials, including the EVEREST trial on adjuvant everolimus.

His recent publications demonstrate a strong trend toward translational research, combining advanced imaging (e.g., 68Ga-FAP PET), immune profiling, and real-world data analysis. Themes include treatment optimization, surgical outcomes, and patient-centered care.

Scientific Awards and Honors:

• Westinghouse Science Talent Search, 7th Place (1987)
• Magna cum laude, Harvard College (1991)
• Alpha Omega Alpha, Johns Hopkins (1995)
• Third Prize, Northern California Urology Residents Seminar (1999)
• Pfizer Scholar in Urology (2001)
• Joseph F. McCarthy Essay Contest, 3rd Place, Western Section AUA (2002)
• Prostate Cancer Research Fellow (2004)
• William R. Smart Distinguished Teaching Award (selected by residents) (2005)
• Excellence in Direct Teaching, Academy of Medical Educators, UCSF (2006)
• Ambrose/Reed Socioeconomic Prize Essay (AUA) (2006)
• AUA Leadership Program (1 of 16 selected nationally biennially) (2006)
• Miley B. Wesson Essay Contest, 2nd Place, AUA

Dr. Meng is a dedicated educator and mentor, recognized for excellence in teaching by residents and peers. He has been involved in national leadership initiatives and contributes to shaping urologic oncology education and policy. Although specific grant details are not listed, his participation in multicenter trials like SWOG S0931 indicates substantial research funding and collaborative leadership.

He is actively involved in multidisciplinary research teams, including those focused on cancer immunology, health economics, and molecular diagnostics. His collaborations span institutions and specialties, reflecting a comprehensive, team-based approach to advancing urologic cancer care.